Case Studies
Multivariate Prioritization of Putative Targets, Indications and Specific Therapeutic Modalities
Case Study
Mar 25, 2022
Portfolio Strategy and Opportunity Assessment to Support BD Decisions and Clinical Development
Case Study
Feb 25, 2022
Modeling To Inform Payer Communications and Policy – Optimizing Treatment Sequences in Multiple Immunology Indications
Health systems view low-cost therapeutic alternatives (biosimilars and generics) as opportunities to reduce their medicine spend. However, this approach focuses on costs only and not outcomes, which results in the adoption of ‘low-cost first’ blanket policies regardless of biologic class or therapy area. Consequently, patients are left to cycle through low-cost options before they can access the most effective treatments
Case Study
Feb 18, 2022
Building a Rare Oncology Brand
Case Study
Feb 7, 2022
Value Proposition of Next Gen PD-L1 + CTLA-4 Antibodies
Case Study
Jan 25, 2022
Terms Sheets, Advising on Deal Structure and ID Qualifying Partners
Case Study
Jan 14, 2022
Commercial Assessment and Business Development / Out-Licensing Support
seeking to pursue clinical development and commercialization of key program and pursue partnering opportunities and out-licensing options...
Case Study
Jan 14, 2022
Due Diligence Facilitation to Prepare for Deal Negotiations
Case Study
Jan 14, 2022
Scenario and Competitor Strategic Planning for a Gene Therapy in Rare Disease
Case Study
Jan 8, 2022
Understanding the Strategy Behind Viral Vector Selection in Ex Vivo and In Vivo Gene Therapies
Case Study
Nov 24, 2021
Activating Medical Affairs to Drive Competitive Differentiation Over the Pre-Launch to Early Post-Launch Period
Enhancing global medical affairs launch support of a bispecific asset by deepening understanding of the competitive challenge and strengthening medical science liaison (MSL) teams’ assertiveness in their approach and interactions with customers
Case Study
Oct 24, 2021